NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 91.71 |
| Open | 90.65 |
| Bid | 82.00 x 1000 |
| Ask | 99.89 x 1200 |
| Day's Range | 89.65 - 92.66 |
| 52 Week Range | 67.33 - 126.98 |
| Volume | 738,713 |
| Avg. Volume | 817,615 |
| Market Cap | 8.16B |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | Feb 11, 2019 - Feb 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 131.64 |
- Thomson Reuters StreetEvents•yesterday
Edited Transcript of NBIX earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Neurocrine Biosciences Inc Earnings Call
- Zacks•2 days ago
Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%
Neurocrine (NBIX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- ACCESSWIRE•3 days ago
Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Amarin
NEW YORK / ACCESSWIRE / November 14, 2018 / U.S. equities closed down on Wednesday as tech giant Apple closed near bear-market territory and another drop in oil prices raised concerns of a global economic ...
- PR Newswire•4 days ago
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), today presented for the first time additional results from two replicate pivotal Phase 3 clinical trials (ELARIS UF-1 (M12-815) and ELARIS UF-2 (M12-817)) evaluating the efficacy and safety of elagolix in women with uterine fibroids. These results were presented at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology in Las Vegas, NV. At the final month of the six-month treatment period, results demonstrated that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding associated with uterine fibroids compared to placebo.
- InvestorPlace•6 days ago
5 Pharma Stocks to Stay Away From
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.
- GlobeNewswire•9 days ago
Report: Developing Opportunities within Louisiana-Pacific, Neurocrine Biosciences, Tahoe Resources, Loews, Quotient Technology, and Evolent Health — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•11 days ago
Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Jefferies 2018 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on Wednesday, Nov. 14, 2018, in London. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference. Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders.
- Simply Wall St.•11 days ago
Does Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Debt Level Pose A Problem?
The size of Neurocrine Biosciences Inc (NASDAQ:NBIX), a US$10.0b large-cap, often attracts investors seeking a reliable investment in the stock market. Market participants who are conscious of risk tend to Read More...
- Zacks•13 days ago
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of 8.33% and 0.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
Neurocrine: 3Q Earnings Snapshot
The San Diego-based company said it had profit of 52 cents per share. The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings ...
- PR Newswire•13 days ago
Neurocrine Biosciences Reports Third Quarter 2018 Financial Results
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx Expanded Clinical Development Pipeline - Phase I Studies Initiated with a Novel VMAT2 Inhibitor and ...
- ACCESSWIRE•13 days ago
Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / U.S. equities rolled back on Friday, ending a 3-day consecutive gain after confusing headlines about the trade talks with China. President Trump announced ...
- Zacks•16 days ago
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
- Zacks•18 days ago
Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?
Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.
- Zacks•20 days ago
Neurocrine Biosciences (NBIX) Q3 Earnings Preview: What to Look Out For
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Market Realist•24 days agoHow Wall Street Analysts View Alkermes after Q3 Earnings Release
On October 24, Alkermes (ALKS) stock closed at $40.03, which is 44% below its 52-week high of $71.22 on February 16. On October 23, the stock closed at $40.19, which is a ~3.42% rise from its prior day’s close of $38.86. Also on October 23, Alkermes hit its 52-week low of $37.01. In September, Alkermes announced that it has initiated an expansion of its ongoing Phase 1 trial.
Market Realist•24 days agoAlkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter financial results on October 23. It generated net revenues of $248.7 million compared to $217.4 million in the third quarter of 2017. That was a 14% YoY (year-over-year) growth.
- PR Newswire•26 days ago
Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress
SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present new data analyses on the long-term effects of INGREZZA® (valbenazine) capsules in adults with tardive dyskinesia (TD) and from RE-KINECT, the largest real-world screening study of patients with possible TD. INGREZZA is the first U.S. Food and Drug Administration (FDA) approved treatment for adults with TD, a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.
Market Realist•last monthHow Acadia Pharmaceuticals Is Positioned Financially
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
- PR Newswire•last month
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9176 (US) or 785-424-1667 (International) using the conference ID: NBIX.
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Technologies, Quaker Chemical, Sealed Air, KLA-Tencor, and Summit Hotel Properties — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Tesaro and Neurocrine Biosciences
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
- Zacks•last month
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
- PR Newswire•last month
Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
SAN DIEGO and BOSTON, Oct. 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders. The collaboration will leverage Jnana's proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine's research and development expertise in CNS disorders to advance new medicines.
